Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
Kuano is aiming to transform the discovery of enzyme inhibitor drugs using a platform that combines quantum transition state simulation and AI led chemistry. Enzyme catalysis occurs via thermodynamically favoured quantum transition states, which represent an attractive conformation for targeting enzyme inhibitors. Kuano’s proprietary in silico approach rapidly simulates the quantum transition state and generates […]
Nuevocor is a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies. The company’s lead programme is an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene. The company also plans to address other untreatable cardiomyopathies using their novel target discovery platform. […]
In the past three months we’ve featured 11 emerging biotech startups — selected from the VentureRadar Database — working on a range new approaches to tackling major diseases. You can find out more about all the companies in the summaries below. Cutanos Cutanos is developing dermal targeted delivery systems for novel vaccines and immunotherapies via […]